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Abstract
Background: Griffithsin, a 121-residue protein isolated from a red algal Griffithsia sp., binds high mannose N-linked glycans
of virus surface glycoproteins with extremely high affinity, a property that allows it to prevent the entry of primary isolates
and laboratory strains of T- and M-tropic HIV-1. We used the sequence of a portion of griffithsin’s sequence as a design
template to create smaller peptides with antiviral and carbohydrate-binding properties.
Methodology/Results: The new peptides derived from a trio of homologous b-sheet repeats that comprise the motifs
responsible for its biological activity. Our most active antiviral peptide, grifonin-1 (GRFN-1), had an EC50 of 190.8611.0 nM in
in vitro TZM-bl assays and an EC50 of 546.6666.1 nM in p24
gag antigen release assays. GRFN-1 showed considerable
structural plasticity, assuming different conformations in solvents that differed in polarity and hydrophobicity. Higher
concentrations of GRFN-1 formed oligomers, based on intermolecular b-sheet interactions. Like its parent protein, GRFN-1
bound viral glycoproteins gp41 and gp120 via the N-linked glycans on their surface.
Conclusion: Its substantial antiviral activity and low toxicity in vitro suggest that GRFN-1 and/or its derivatives may have
therapeutic potential as topical and/or systemic agents directed against HIV-1.
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Introduction
Preventing HIV-1 infection is the primary goal of pre- and post-
exposure prophylaxis of HIV. Prophylactic modalities that block
HIV-1 entry would be particularly valuable, because latent HIV-1
infections are typically refractory to therapeutic or immunological
interventions [1–9]. Lectins, especially those targeting the high
mannose, N-linked glycans of HIV surface glycoproteins [10], are
exceptionally potent HIV entry inhibitors. Most anti-HIV lectins
have been identified in and isolated from natural sources. They
include cyanovirin-N [11,12] and scytovirin [13] from cyanobac-
teria, contrajervin and treculavirin from moraceous plants [14], and
the h-defensin peptides of non-human primates [15–19]. Among
these, the red algal protein griffithsin (GRFT) [20] stands out as
having the most potent anti-HIV inhibitory activity, with an average
EC50 of 40 pM [20,21]. GRFT has been produced recombinantly
in Escherichia coli [22,23] and, in larger quantities, in Nicotiana
benthamiana plants [24]. GRFT forms homodimers whose binding
to high mannose oligosaccharides blocks the binding of gp120 to
CD4-expressing cells. Notably, the three almost identical carbohy-
drate binding sites on each monomer of GRFN [23,25–27] are
formed by Tyr and Asp residues in these functional repeats (Figure 1).
In addition to high potency [24], GRFT showed stability over a
satisfactory pH and temperature range, caused minimal toxicity,
and did not induce the release of proinflammatory cytokines that
might recruit potential HIV-susceptible target cells to the target
mucosa. These desirable properties make GRFT an excellent
candidate microbicide [28], as well as an intriguing starting point
for the design of smaller peptide-based antiviral minilectins
directed against high mannose sugars.
As only two entry inhibitors, FuzeonH (T20, Enfuvirtide) and
Maraviroc, are currently in clinical use, there is a need for new
entry inhibitors [29–34] that could be used topically to prevent
infection, or systemically to treat patients with drug-resistant HIV.
Since the systemic use of non-human proteins, including griffithsin
or cyanovirin-N, may be time-limited by their immunogenicity,
smaller griffithsin-derived peptides may present a more suitable
alternative for such applications.
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This report describes Grifonin-1 (GRFN-1), an 18-residue
peptide with glycan-binding and HIV-inhibitory properties,
derived from the b-sheet core of griffithsin.
Materials and Methods
Ethics Statement
Venous blood samples (uncoded) were collected in the
Department of Medicine at UCLA, by a qualified person under
the approved Institutional Review Board protocol (IRB #92-11-
596-41) after obtaining written consent from participants.
Primary vaginal epithelial cells (VECs) were purchased from
MatTek Corp., (Ashland, MA USA) and provided with no
identifiers not allowing direct identification of the donors.
Peptide synthesis and characterization. All peptides were
synthesized by the solid phase method using a CEM Liberty
automatic microwave peptide synthesizer (CEM Corporation,
Matthews, NC), applying 9-fluorenylmethyloxycarbonyl (Fmoc)
chemistry [35]. Amino acid derivatives and reagents were from
EMD Biosciences (San Diego, CA) and Chem-Impex International
(Wood Dale, IL). Rink Amide MBHA resin from EMD Biosciences
(San Diego, CA) was used as a solid support. Peptides were cleaved
from the resin with modified reagent K (TFA 94% (v/v); phenol,
2% (w/v); water, 2% (v/v); TIS, 1% (v/v); EDT, 1% (v/v); 2 hours)
and precipitated by adding ice-cold diethyl ether. Reduced peptides
were purified by preparative reverse-phase high performance liquid
chromatography (RP-HPLC) to .90% homogeneity and their
purity evaluated by matrix-assisted laser desorption ionization
spectrometry (MALDI-MS) and analytical RP-HPLC.
Disulfide bond formation. Peptides were dissolved at a final
concentration of 0.25 mg/ml in 50% DMSO in H2O and stirred
overnight at room temperature. Subsequently, the peptides were
lyophilized and re-purified on a preparative C18 Symmetry-
ShieldTM RP-HPLC column to .95% homogeneity and their
purity was evaluated by MALDI-MS and analytical RP-HPLC.
Analytical HPLC. Analytical RP-HPLC was performed on a
Varian ProStar 210 HPLC system equipped with ProStar 325 Dual
Wavelength UV-Vis detector with the wavelengths set at 220 nm and
280 nm (Varian Inc., Palo Alto, CA). Mobile phases consisted of
solvent A, 0.1% TFA in water, and solvent B, 0.1% TFA in
acetonitrile. Analyses of peptides were performed with an analytical
reversed-phase C18 SymmetryShieldTM RP18 column, 4.66250 mm,
5 mm (Waters Corp., Milford, MA) applying a linear gradient of
solvent B, from 0 to 100%, over 100 min with a flow rate of 1 ml/min.
All biological and biophysical experiments presented in the
article were performed using unfractionated heterogeneous
mixture of oligomers of GRFN peptide(s) (please see Analytical
ultracentrifugation section).
Griffithsin (GRFT). Recombinant His-Tagged griffithsin
(Cat#11610) was obtained through the AIDS Research &
Reference Reagent Program, Division of AIDS, NIAID, NIH.
Binding studies. Surface plasmon resonance (SPR) studies
were performed on a BIAcore 3000 system (BiaCore AB,
Piscataway, NJ), using BIAcore CM5 sensor chips and HBS-EP
running buffer (pH = 7.4) containing 10 mM HEPES, 150 mM
NaCl, 3 mM EDTA, and 0.005% polysorbate 20. Proteins/
peptides were immobilized on a CM5 sensor chip using the amine
coupling method. The chip was activated by mixing 400 mM N-
ethyl-N-(3-dimethylaminopropyl)-carbodiimide hydrochloride and
100 mM N-hydroxysuccinimide. Residual reactive groups on the
chip surface were blocked using 1.0 M ethanolamine/HCl
(pH = 8.5). The flow cell-1 chamber, which served as a control,
lacked immobilized protein but was treated with N-ethyl-N-
(3-dimethylaminopropyl)-carbodiimide hydrochloride, N-hydro-
xysuccinimide, and ethanolamine/HCl. Binding signals were
corrected for nonspecific binding by subtracting the flow cell-1
signal. To regenerate chip surfaces, bound ligands were removed
with 10 mM HCl. Data were analyzed with BIAevaluation 4.1
software (Biacore, Piscataway, NJ).
Saccharides. a-D-mannopyranose (Man), L-fucopyranose (Fuc),
a-D-galactopyranose (Gal), sialic acid (N-acetyl-neuraminic acid,
Neu5Ac), N-acetyl-glucosamine (GlcNAc) and Man3(GlcNAc)2, a
core pentasaccharide found in most N-linked oligosaccharides. All
of these saccharides were purchased from Sigma-Aldrich (St. Louis,
MO).
Antiviral activity studies
Luciferase reporter assay (TZM-bl assay). [36] The
ability of the analogs to inhibit HIV infection was determined
with an assay that determines viral infectivity with an LTR-
mediated luciferase reporter construct [37]. In brief, TZM-bl
reporter cells are HeLa-derived JC53-BL cells that express high
levels of CD4, CXCR4, and CCR5. They also contain reporter
cassettes for luciferase and b-galactosidase, both driven by the
HIV-1 long terminal repeat [38]). 24 hr after these reporter cells
were exposed to R5 lab-adapted strains of HIV-1 (BaL) in the
presence of peptides, protection was measured as % reduction in
luciferase activity (relative light units) compared to cells infected
with virus and peptide vehicle alone.
p24gag antigen release assay. As previously described [15],
immortalized CD4+ lymphoblastic PM1 cells, (1.56105/100 ml)
were incubated with virus (BaL) (MOI = 1022) in the presence or
absence of 0.078–5 mM of GRFN-1 for 3 hrs at 37uC/5% CO2.
The cells were washed and resuspended in fresh growth media
containing vehicle or peptides for 7 days. Supernatants were
collected at days 3, 5, and 7 post-infection, and on days 3 and 5 the
cells were resuspended in 1 ml of growth medium containing the
appropriate concentration of vehicle or peptide. HIV-1 infection
was quantified by measuring the amount of p24gag in the cell
supernatants (Perkin Elmer p24 ELISA, Waltham, MA). Day 5
supernatants were determined to represent the peak infection day
in PM1 cells.
Figure 1. Sequence of the griffithsin and comparison of the functional repeats (boxed) in its structure. Position of the unknown amino
acid X31 (shaded) is occupied by Ala in the expressed variant of the protein.
doi:10.1371/journal.pone.0014360.g001
Griffithsin Derived Antivirals
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Cell viability and cytotoxicity. Cell viability experiments
were carried out using CytoTox-GloTM Assay (Promega Corp.,
Madison, WI) and cytotoxicity was analyzed using an MTT-based
cell proliferation kit (Boehringer Mannheim, Indianapolis, IN)
Both tests were performed according to manufacturer’s instruc-
tions. MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide. Experiments utilizing vaginal epithelial cells (VECs) were
carried out as previously described [49].
Human red blood cells (hRBCs). Heparinized fresh blood
(,3 ml) was collected from an anonymous donor. A 200 ml aliquot
was removed and washed 46with 800 ml of cold PBS at RT for
3 min at ,5006g. After each centrifugation, 780 ml of supernatant
was removed. After the last wash, the supernatant was completely
removed and the packed red blood cells were diluted 1:20 in PBS to
prepare a 5% v/v stock suspension of hRBCs.
Primary vaginal epithelial cells. (VECs) were purchased
from MatTek Corp., (Ashland, MA USA) and maintained
according to provided protocol.
Hemolysis assay. As previously described [39], 2.5% v/v
normal human RBCs were exposed to various concentrations of
GRFN-1 at 37uC for 30 min. All experiments were carried out in
triplicate using 96-well microplate (Costar 3596) and the OD at
700 nm was monitored every 30 s. employing the SpectraMAX 250
microplate reader (Molecular Devices, Sunnyvale, CA). Controls
included PBS, untreated human RBCs, and human RBCs +2.5%
Triton (100% lysis). The hemolytic effect was calculated as follows:
%Hemolysis~100| 1{
A700{Sample{A700{100%Lysis
A700{NoLysis{A700{100%Lysis
 
Inflammatory response was assessed using Bio-Plex Human
Cytokine Multiplex Assays (Cat# M50-0KCAF0Y & MF0-
005KMII, Bio-Rad Laboratories, Inc., Hercules, CA). Briefly,
human peripheral blood mononuclear cells and primary vaginal
epithelial cells (VECs) were cultured with 0–100 mM of GRFN-1
in appropriate media. After 24 h supernatants were collected and
assayed according to manufacturer’s protocol. Only data for
factors with readable, ‘‘in range’’ values are presented.
Circular dichroism (CD) analyses of secondary
structure. CD spectra from 185–260 nm of GRFN-1 were
examined in different solution environments using a JASCO 720
spectropolarimeter (Jasco, Easton, MD) calibrated for wavelength
and optical rotation with 10-camphorsulphonic acid [40,41]. Peptide
was scanned at 20 nm per minute in a 0.01 cm path-length cell at
25uC with a sample interval of 0.2 nm. The peptide concentration
was determined by UV absorbance at 280 nm. After baseline
correction, spectra were expressed as the Mean Residue Ellipticity
[h]MRE. Quantitative estimates of secondary structural contributions
were made with Selcon [42] using the spectral basis set for proteins in
the Olis Global WorksTM software package (Olis Inc., Bogart, GA).
Fourier transform infrared (FTIR) spectroscopy. Infrared
spectra were recorded at 25uC using a Bruker Vector 22TM FTIR
spectrometer with a deuterated triglycine sulfate (DTGS) detector,
and averaged over 256 scans at a gain of 4 with a resolution of
2 cm21. Peptide samples were initially freeze-dried several times
from 10 mM HCl in D2O to remove any interfering counter ions
and residual H2O. Solution spectra of peptides were made in
deuterated 10 mM phosphate buffer, pD = 7.4 (pD = pH+0.4)
and in structure promoting mixed solvent-buffer solutions
(trifluoroethanol (TFE) or hexafluoroiso propanol (HFIP). Spectra
were acquired using a temperature controlled, demountable liquid
cell with calcium fluoride windows fitted with a 50 mm thick spacer
(Harrick Scientific, Pleasantville, NY). The relative proportions of
a-helix, b-turn, b-sheet, and disordered conformations of solu-
Figure 2. The structure of griffithsin. Panel A: Dimer of griffithsin (PDB entry code 2GTY, [23]). Fragments corresponding to GRFN-1/2 and GRFN-
3 are in red and in blue respectively. Remaining homological domain necessary to form core of the griffithsin’s monomer is in green. Panel B: Core of
griffithsin. Residues Tyr28, Tyr68 and Tyr110, which are components of monosaccharides’ binding domain, are in magenta.
doi:10.1371/journal.pone.0014360.g002
Table 1. Sequences of Grifonins (GRFNs).
Peptide Sequence
GRFN-1 Cha-SC-Chg-R-Chg-RSGSY-Cha-DN-Chg-R-Chg-(D)Cys-
CONH2
GRFN-2 Cha-SC-Chg-R-Chg-RSGSY-Cha-DR-Ch\g-R-Chg-(D)Cys-
CONH2
GRFN-3 Chg-CR-Chg-R-Chg-RSGDY-Chg-DR-Chg-R-Cha-(L)Arg-
(D)Cys-CONH2
Cysteins forming intra-molecular disulfide bonds are bolded. Cha-(L)-Cyclohexyl-
alanine, Chg-(L)-Cyclohexyl-glycine, (D)Cys-(D)-Cysteine.
doi:10.1371/journal.pone.0014360.t001
Table 2. Analytical data of GRFN peptides.
Peptide Composition MW (g/mole) Calc/Found RT (min)
GRFN-1 C102H167N29O25S2 2263.78/2264.41 40.241
GRFN-2 C104H173N31O24S2 2305.86/2306.61 39.100
GRFN-3 C113H190N38O25S2 2545.14/2546.12 32.602
RT- retention time.
doi:10.1371/journal.pone.0014360.t002
Griffithsin Derived Antivirals
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tion and multilayer IR spectra were determined by Fourier
self-deconvolution for band narrowing and area calculations of
component peaks of the FTIR spectra using curve-fitting software
supplied by Galactic Software (GRAMS/AI, version 8.0; Thermo
Electron Corp., Waltham, MA). The frequency limits for the
different structures were: a-helix (1662–1645 cm21), b-sheet (1637–
1613 and 1710–1682 cm21), turns (1682–1662 cm21), and
disordered or random (1650–1637 cm21) [43].
Molecular dynamics modeling. The starting structure for
GRFN-1 was obtained by using Hyperchem 7.5 (http://www.
hyper.com) to template the peptide structure in a beta hairpin
conformation derived from segments of the griffithsin protein (PDB
2GTY, residues 18–31). These monomeric starting structures were
placed in a periodic 56A˚3 box of TIP4P water and the ensemble was
neutralized with counter ions to simulate the environment used for
the experimental CD measurements. The peptide in the solution
box was conjugate-gradient minimized using the Polak-Ribiere
approach implemented in Hyperchem. The minimized monomeric
GRFN-1 ensemble was ported to the Gromacs program suite,
version 4.0.4 (http://www.gromacs.org), and subjected to the
steepest descent method using the OPLS_AA option [44].
The system was subjected to 20 psec of pre-run molecular
dynamics at 300uK allowing the solvent to equilibrate while
restraining the peptide. After pre-run solvent equilibration, the
peptides were subjected to 50 nsec of free MD simulations at 300uK
without any experimental constraints, utilizing Berendsen tempera-
ture and pressure coupling and the Particle Mesh Ewald method for
evaluating long-range electrostatic interactions. The time-dependent
evolution of the peptide secondary structure (i.e., analyzed using the
DSSP criteria [45] for the peptide in the water environment indicated
when equilibrium was reached. Molecular model illustrations were
rendered using PyMOL v0.99 (http://www.pymol.org).
Analytical ultracentrifugation. Sedimentation equilibrium
was performed at 20uC in a Beckman Optima XL-A analytical
ultracentrifuge using absorption optics at 280 nm. Twelve mm
path length double sector cells were used for all samples. Samples
(OD280 = 0.7 and OD280 = 0.15)) were in 20 mM NaH2PO4.
Sedimentation equilibrium profiles were measured at speeds of
3000, 7000, 11000, 24000 and 36000 rpm. The data were fitted
with a nonlinear least-squares exponential fit for a single ideal
species using the Beckman Origin-based software (Version 3.01 A
partial specific volume of 0.739 was estimated from the amino acid
composition [46] using 0.9 (the partial specific volume of a leucine
residue) for the partial specific volume of cyclohexylalanine and
cyclohexylglycine. It was then corrected to 20uC [47].
Results
Design and synthesis of Grifonins (GRFNs)
The remarkable reported activity of griffithsin against labora-
tory strains and primary isolates of T- and M-tropic HIV-1
prompted us to perform a detailed structural analysis of this
protein as the first stage of our attempt to design small peptidic
analogs that potentially could mimic the anti-viral properties of the
native griffithsin.
Structurally, three homologous b-sheet domains (residues 20–
34, 58–76 and 96–120) form the protein’s core (Figures 1 & 2)
and contain the functional repeats responsible for its carbohy-
drate-binding [23]. Since the protein lacks disulfide bonds, its
integrity is most likely maintained by hydrophobic and ionic
interactions. We theorized that each b-sheet domain can either act
independently as an entry inhibitor and/or assemble into the
higher order structures resembling those of native griffithsin.
Consequently, some of our peptide analogues contained unusual
amino acids and/or structural features not present in native
griffithsin to impose secondary structural features, which we
hypothesized might be important for activity and multimerization.
Specifically, we introduced varying numbers of cyclohexylalanine
Figure 3. Analytical data for GRFN-1. (A) analytical HPLC profile and (B) MS spectra.
doi:10.1371/journal.pone.0014360.g003
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(Cha) and cyclohexylglycine (Chg) residues that might ‘‘dial-up’’
hydrophobic interactions between monomers and possibly in-
crease assembly of higher order structures (desirably trimers).
Some analogs also contained a disulfide bridge to stabilize b-
hairpin-monomer structure. After re-evaluating the initial group of
compounds with respect to their composition, hydrophobicity and
ease of synthesis, we concluded that 3 analogues shown in Table 1
were feasible for further development. An attempt to obtain folded
(oxidized) GRFN-1 directly on the solid support using thalium
trifluoroacetate ((CF3COO)3Tl) protocol [48] was unsuccessful.
Consequently, after solid-phase synthesis, the linear peptides were
oxidized in 50% DMSO to form the desired b-hairpin GRFNs.
Analytical data for synthesized peptides are presented in Table 2
& Figure 3.
Antiviral activity of GRFNs
Initially, grifonins 1–3 were screened in a standard HIV-1
reporter assay (Figure 4A). Dose response experiments revealed
that GRFN-1 was the most potent analog and that it maintains
high activity at low mM concentrations. Consequently we chose
GRFN-1 as our lead compound and re-tested a broader range of
concentrations in the TZM-bl assay as well as in the more
stringent p24gag antigen release assay using immortalized CD4+
lymphoblastic PM1 cells (Figure 4B). This 18 amino acid long
peptide showed considerable activity in both assays with EC50
values 190.8611.0 nM and 546.6666.1 nM for TZM-bl and
p24gag antigen release assays respectively. GRFN-1 was also more
potent than retrocyclin (RC)-101, which had an EC50 of
3,404691 nM in the TZM-bl assay. RC-101, which served as
positive control, is a humanized h-defensin, which is being
developed as a prospective topical microbicide [49]. However,
GRFN-1 was significantly less active than the parental protein
griffithsin (Figure 4C) that in our hands showed potent activity in
low picomolar range (EC50 = 19.661.9 pM). Both, griffithsin and
GRFN-1 maintained their antiviral activity in PBMC based p24gag
antigen release assays toward CXCR4 (HIV-1IIIB) as well as
CCR5 (HIV-1BAL) strains (Figure 4D).
GRFN-1 binds viral glycoproteins
As N-linked glycans are the molecular target(s) of griffithsin, we
sought to determine whether GRFN-1 acts via similar mechanism.
To ascertain this, we performed two types of surface plasmon
resonance (SPR) binding experiments. In the first set, we
established that GRFN-1 binds gp41, gp120BAL and gp120LAV
in a dose dependent manner (Figure 5A–C) with KD values in
low micromolar range (KD = 1.0660.22 to 3.0061.31 mM).
Figure 5D shows that the KD (0.5060.13 mM) for the self-
association of GRFN-1 was considerably below its KD for binding
to the aforementioned viral glycoproteins. This finding suggested
that GRFN-1 acts as a multimer rather than as a monomer.
Figure 4. Antiviral activity of GRFNs. Panel A: Comparison of dose response experiments of GRFNs in TZM-bl assay. Panel B: Comparison of dose
response experiments of GRFN-1 in TZM-bl assay (EC50 = 190.8611.0 nM) and p24
gag antigen release assay (EC50 = 546.6666.1 nM) with RC-101 in
TZM-bl assay (EC50 = 3404.0691 nM). RC-101 is a h-defensin which is currently being developed as topical microbicide. Panel C: Antiviral activity of
griffithsin (GRFT) in TZM-bl assay (EC50 = 19.661.9 pM). Panel D: Comparison of antiviral activity of GRFT and GRFN-1 in p24
gag antigen release assay
using PBMCs and CXCR4 (HIV-1IIIB) and CCR5 (HIV-1BAL) strains.
doi:10.1371/journal.pone.0014360.g004
Griffithsin Derived Antivirals
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Binding to N-linked glycans was additionally confirmed in
competition experiments employing various saccharide compo-
nents of such glycans: mannose (a-D-mannopyranose, Man),
fucose (L-fucopyranose, Fuc), galactose (a-D-galactopyranose Gal),
sialic acid (N-acetyl-neuraminic acid, Neu5Ac), N-acetyl-glucos-
amine (GlcNAc) and common core pentasaccharide Man3-
GlcNAc2 (Figure 6 & Supporting Information S1). Although
GRFN-1 interacted with all of these sugars, except fucose, in the
range of concentrations tested, the most effective competitors were
GlcNAc and mannose.
Cytotoxicity and pro-inflammatory properties
Since systemic uses would typically require either intravenous or
subcutaneous administration of the GRFN-1, we performed
hemolysis assays using various concentrations of the peptide and
human red blood cells (hRBCs) (Table 3 & Figure 7). The
compound showed low hemolytic activity (,10%) toward hRBC
at the highest concentration tested (20 mM) and was not hemolytic
at concentrations below 2.5 mM. Toxicity studies of GRFN-1 with
TZM-bl cells (Figure 8) showed no effect on viability, although
Figure 5. Binding of GRFN-1 to viral glycoproteins. Binding to: (A) gp120LAV, (B) gp120BAL, (C) gp41 and (D) GRFN-1 (self-association). KD6SEM
values were calculated as an average from at least 5 independent experiments.
doi:10.1371/journal.pone.0014360.g005
Figure 6. Examples of SPR competition experiments of GRFN-1 with saccharide(s) using gp120LAV chip. (A)- galactose, (B) Man3GlcNAc2
(‘‘core pentasaccharide’’).
doi:10.1371/journal.pone.0014360.g006
Griffithsin Derived Antivirals
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the peptide appeared to inhibit cellular dehydrogenase activity (as
gauged by MTT reduction) in a dose dependent manner. Studies
with primary vaginal epithelial cells (VEC), peripheral blood
mononuclear cells and PM1 cells showed similar effects (Figure 9)
although actual level of metabolic inhibition was strongly
dependent on cell type.
One of the important properties of antivirals is lack of pro-
inflammatory properties. We tested GRFN-1 for such properties
using human PBMCs and primary VECs. Cells were treated with
the peptide for 24 hr and subsequently supernatant was analyzed
using Bio-Plex Human Cytokine Multiplex Assays (Bio-Rad
Laboratories, Inc., Hercules, CA) for various pro-inflammatory
cytokines and growth factors. Results are presented in Support-
ing Information S1. We found a number of factors to be either
unchanged or decreased after treatment with GRFN-1. These
include IL-5, IL-8, IL-10, IL-13, VEGF, IFN-c, TNF-b, GM-
CSF, MIP-1a and others. Notably, reverse effect of GRFN-1
treatment was also observed for limited number of pro-
inflammatory factors.
Secondary structure analysis of GRFN-1
Analysis by FTIR spectroscopy. Analysis of the secondary
structure of GRFN-1 in solvent systems of varying polarity are
shown in Figure 10A. In aqueous buffer the peptide has a
dominant b-sheet structure (Table 4). In less polar environments
such as the amphipathic TFE:buffer solvent system and the more
hydrophobic HFIP:buffer environment, there was a shift from b-
sheet to more helical conformations with greatest helical
propensity in the more hydrophobic environment (Table 4).
These observations suggest that the GRFN-1 peptide can assume
different conformations, depending on the polarity of the solvent.
Analysis by CD spectroscopy. The conformational plasti-
city of GRFN-1 was further studied by CD spectroscopy. In
10 mM phosphate buffer, pH = 6.5, GRFN-1 shows a concen-
tration dependent change in secondary structure (Figure 10B). At
250 mM, almost equal proportions of a-helix, b-sheet, turn and
disordered conformations are present. However, at 500 mM the b-
sheet structure increases at the expense of a-helix (Table 5). In
contrast to the concentration-dependent secondary structural
changes in aqueous buffer, the conformation of GRFN-1 in
structure-promoting solvent systems such as TFE:buffer and
HFIP:buffer (Figure 10C) had dichroic minima at 222 and
208 nm with a maximum near 193 nm. These features, charac-
teristic of peptides with more helical conformations [50], were not
concentration dependent over the range of 50 to 500 mM (data not
shown). Analysis of the CD spectra with curve-fitting algorithms
(Table 5) reveal that GRFN-1 had a dominant helical
conformation in HFIP:buffer and a mix of a-helix, b-sheet, turns
in TFE:buffer suggesting that the peptide has a polarity dependent
polymorphism.
Table 3. Hemolytic effect of GRFN-1 on human red blood
cells (hRBCs).
Concentration (mM) Hemolysis±SEM (%)
20 10.364.3
10 7.361.3
5 2.862.3
2.5 1.260.7
#1.25 Non hemolytic
doi:10.1371/journal.pone.0014360.t003
Figure 7. Stability of human RBCs in the presence of various
concentrations of GRFN-1.
doi:10.1371/journal.pone.0014360.g007
Figure 8. Viability (blue) and % of cell metabolism inhibition
(red) of TZM-bl cells in the presence of various concentrations
of GRFN-1.
doi:10.1371/journal.pone.0014360.g008
Figure 9. Inhibition of cell metabolism by various concentra-
tions of GRFN-1 (MTT assay) determined in primary vaginal
epithelial cells (VEC), human peripheral blood mononuclear
cells (PBMC) and PM1 cells (continuously CD4+ T-cell line, [52]).
doi:10.1371/journal.pone.0014360.g009
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Molecular dynamics simulations
To further investigate similarities between their structural
elements, molecular dynamics simulations were performed using
the conformation of griffithsin residues 18–31 as a homology
template for the starting structure of GRFN-1. The templated
structure was then subjected to 50 nsec of dynamics without
constraints to refine the structure. The DSSP plot (Figure 11)
indicates that the peptide assumes a stable secondary structure
with well defined loop and b-sheet segments. This disposition of
secondary structure in the peptide construct is very similar to that
observed in the parent griffithsin crystal structure (Figure 12) and
is consistent with the type and amount of secondary structure
observed experimentally in the FTIR and CD measurements of
the GRFN-1 peptide in aqueous medium.
Analytical ultracentrifugation
Sedimentation equilibrium suggests that GRFN-1 in diluted salt
is present as high molecular weight soluble aggregates with some
monomer present. When initially dissolved in 20 mM NaH2PO4
the peptide gave a slightly turbid solution. Very little (less than 5%)
of the OD280 was lost on centrifugation at 3000 rpm. Early scans
(after 16 hours of centrifugation) suggested the sample was quite
heterogeneous, with a weight-average molecular weight of about
150,000. The samples were then examined at higher speeds.
Approximately two-thirds of the OD280 was lost at 7000 rpm, with
the remaining material being heterogeneous (as seen by the non-
random residuals from a single-exponential fit visible in Sup-
porting Information S1 with a weight-average molecular
weight of about 69000. Further scans at 11000, 24,000 and
36,000 rpm gave successively lower weight-average molecular
weights as the higher molecular weight complexes were removed
by centrifugation (Table 6). By 36,000 rpm the remaining
material (approximately one quarter of the original OD) had a
weight-average molecular weight, 2200, and random residuals
from a single-exponential fit consistent with the remaining
material being reasonably homogeneous monomer.
Discussion
Although 30 years of concerted research have led to impressive
progress in the therapy of patients infected with HIV-1, therapy
remains imperfect and chemoprevention of HIV infections
remains an unmet challenge. In this report we present data for a
novel HIV-1 entry inhibitor, grifonin-1 (GRFN-1), that was
obtained by modifying and truncating the naturally occurring
lectin, griffithsin. GRFN-1 peptide is over 6 times smaller than the
original protein (18 residues vs. 121), and it is only half the size of
FuzeonH (18 vs. 36 residues), a peptidic entry inhibitor in clinical
use. These features make GRFN-1 an attractive compound for
further development.
We initially synthesized 3 closely related analogues (GRFNs 1–
3) that were engineered to form stable b-hairpin structures that
simulated structural features found in the native protein. The
properties of each monomer were further modified to enhance
self-assembly into higher order structure(s) by increasing hydro-
Figure 10. Analysis of GRFN-1 structure. (A) FTIR spectra; (B) CD spectra in in 10 mM phosphate buffer, pH= 6.5 ((---) 0.25 mM; (—) 0.5 mM); (C)
CD spectra in TFE:10 mM phosphate buffer pH= 6.5 (4:6, v:v) and HFIP (---); 10 mM phosphate buffer pH= 6.5 (4:6, v:v) (—).
doi:10.1371/journal.pone.0014360.g010
Table 4. Proportions of different elements of secondary
structure for GRFN-1 peptide in aqueous buffer, TFE-buffer
and HFIP-buffer based on FTIR spectroscopic analysis.
Sample * Conformation (%)
a-helix b-sheet turns disordered
GRFN-1, 0.5 mM in Buffer 12.4 37.6 22.4 27.6
GRFN-1, 0.5 mM in TFE: Buffer 23.2 31.7 20.3 24.8
GRFN-1, 0.5 mM in HFIP:Buffer 48.6 8.4 17.2 25.8
*peptides in 10 mM phosphate buffer pH= 7.5, TFE:10 mM phosphate buffer
pH=7.5 (4:6, v:v) or HFIP:10 mM phosphate buffer pH= 7.5 (4:6, v:v) were
analyzed for secondary conformation based on secondary structural analysis
using GRAMS/AI (Methods).
doi:10.1371/journal.pone.0014360.t004
Table 5. Proportions of different elements of secondary
structure for GRFN-1 peptide in aqueous buffer, TFE-buffer
and HFIP-buffer based on Circular Dichroic spectroscopic
analysis.
Sample * Conformation (%)
a-helix b-sheet turns disordered
GRFN-1, 0.25 mM in Buffer 25.0 24.0 21.0 30.0
GRFN-1, 0.5 mM in Buffer 13.0 35.0 21.0 31.0
GRFN-1, 0.5 mM in TFE: Buffer 19.0 28.0 23.0 30.0
GRFN-1, 0.5 mM in HFIP:Buffer 52.0 8.0 16.0 24.0
*peptides in 10 mM phosphate buffer pH=6.5, TFE:10 mM phosphate buffer
pH=6.5 (4:6, v:v) or HFIP:10 mM phosphate buffer pH= 6.5 (4:6, v:v) were
analyzed for secondary conformation based on secondary structural analysis
using Selcon (Methods).
doi:10.1371/journal.pone.0014360.t005
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phobicity at certain positions (Chg/Cha modifications). Our most
active antiviral peptide, GRFN-1, contained a largely intact loop
region (–24RSGSYLDN31–) modified only by the chemically
conservative substitution of Leu by cyclohexylalanine. The
Asn31/14 residue appeared to be crucial for antiviral activity in
low concentrations since GRFN-2, an otherwise identical peptide
with an Asn to Arg substitution (Figure 4A) was considerably less
active than GRFN-1. Asn31 is not implicated in interactions
responsible for ligand(s) binding [23,25–27], neither it is
responsible for interactions between functional domains. None-
theless, in GRFN-1 it may promote oligomerization since the Asn
side chain may serve as both a donor and acceptor of hydrogen
bonds [51]. Theoretically, inserting a positively charged Arg in the
same position could create a repulsive force based on electrostatic
interactions.
Oligomerization of GRFN-1 in various solvents (water, DMSO
and their mixtures) was suggested in our limited NMR studies
(data not shown). Therefore we decided to research this
phenomenon in a greater detail. SDS-PAGE analysis in non-
reductive conditions was inconclusive (Supporting Informa-
tion S1), however it suggested that dimers of GRFN-1 (,4.5 kDa)
may be stable enough to persist in this relatively ‘‘hostile’’
environment. In addition, SPR experiments demonstrated that
GRFN-1 can self-associate at low micromolar concentrations,
(KD = 0.5060.13 mM) strengthening the likelihood that GRFN-1
oligomers contribute substantially to the activities demonstrated in
our antiviral assays.
Analytical ultracentrifugation experiments provided insight into
the size distribution of GRFN-1 oligomers and/or aggregates,
showing that GRFN-1 forms ensembles that range in size from 2.2
(monomer)2150 kDa (Table 6). Whether these higher order
aggregates of GRFN-1 form any sort of regular structure(s) is
difficult to predict from our data, however a ‘‘multimer-based’’
mode of action in in vitro/in vivo settings is highly probable. This
may also account for the relatively high biological activity of
GRFN-1, considering that the potency of its parental molecule,
griffithsin, seems to be strongly associated with its multivalency
[25]. Indeed, native griffithsin forms a domain swapped dimer
with three almost identical carbohydrate-binding sites in each
monomer. Such a mode of action may be advantageous since
multivalent aggregates are likely to form more stable complexes
with viral glycoproteins. In addition, they may be more resistant to
proteolysis and more persistent in the bloodstream due to size
imposed delay in renal excretion. Notably, based on EC50
obtained in various antiviral assays, our leading compound
(GRFN-1) is approximately 100 to 1000 times less effective than
the parental protein griffithsin. Such a result might be explained
by formation of imperfect oligomers that only partially mimic
spatial arrangement of griffithsin dimer and its carbohydrate
binding centers. In addition, GRFN-1 forms various size oligomers
as illustrated by our ultracentrifugation studies, that is in contrast
with very stable dimers formed by griffithsin. Similarly, stability of
the GRFN-1 oligomers might also impose a detrimental effect on
biological activity, since self-association of the peptide is rather
moderate (KD = 0.5060.13 mM) and complexes may not be
Figure 11. Evolution of GRFN-1 secondary structure as a function of simulation time in aqueous periodic solvent box.
doi:10.1371/journal.pone.0014360.g011
Figure 12. Comparison of GRFN-1 and corresponding griffith-
sin fragment structures. (A) residues 18–35 of griffithsin in blue (PDB
2GTY), (B) structure of GRFN-1 in red and their overlay (C). Structure of
GRFN-1 was obtained from molecular dynamics simulation in water for
50 ns.
doi:10.1371/journal.pone.0014360.g012
Table 6. Analytical ultracentrifugation results.
Speed Molecular weight range (Da)
3K (limited data) ,150000
7K 68500–84700
11K 8950–38100
24K 2541–6200
36K 2245–2940
doi:10.1371/journal.pone.0014360.t006
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‘‘stable enough’’ leading to substantially lower biological activity
outcome.
From our SPR binding studies, GRFN-1 like its parental
molecule, likely acts by binding N-linked carbohydrates on viral
glycoproteins gp41 and gp120. However, competition experiments
revealed certain binding preferences (Supporting Information
S1). Although each of the sugars that we tested, except fucose,
competed with the bindin of GRFN-1 to viral glycans, the
inhibitory effects depended on the carbohydrate’s structure and
concentration. Inhibition of binding by GlcNAc and Gal was
immediate and ‘‘saturated’’ at a molar ratio of ,4:1. D-Mannose
was an especially potent inhibitor that could almost completely
abrogate binding of GRFN-1 to the viral glycoproteins. Inhibition
by sialic acid (Neu5Ac) was less profound and analysis was
complicated by the accumulation of sialic acid, most likely due to
ionic interactions with the peptide.
Given the substantial similarity between the tested carbohy-
drates, it is interesting to speculate why only fucose failed to
compete against GRFN-1’s binding to viral glycoproteins. The
most striking structural difference between fucose and the other
group members is absence of an equatorial hydroxymethyl
(–CH2OH, in red in Figure 13)) in position 5 of the pyranose
ring, which is occupied by a methyl group in fucose. This small
difference seems to be pivotal for binding by GRFN-1. It is
noteworthy that crystallographic analyses of complexes between
griffithsin and various carbohydrates [23,26] demonstrated that
the same hydroxymethyl group plays an important role in the
hydrogen bond network that underlies its carbohydrate interac-
tions- a finding that also underlines mechanistic similarities
between grifithsin and its peptide derivative, GRFN-1.
The presented study identifies a novel 18-residue peptide,
GRFN-1, that manifests potent anti-HIV-1 activity. Its low
toxicity, limited hemolytic/proinflammatory properties, activity
against CCR5 and CXCR4 HIV-1 strains and relatively small size
identifies it as a strong lead candidate for further development as
HIV-1 entry inhibitor for topical or systemic applications.
Supporting Information
Supporting Information S1. With Figures S1, S2, and S3, and
Tables S1 and S2.
Found at: doi:10.1371/journal.pone.0014360.s001 (3.70 MB
PDF)
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